About the Company

Ariosa Diagnostics, Inc., is a molecular diagnostics company committed to innovating together to improve patient care. The flagship product, the Harmony Prenatal Test, is a safe, highly accurate and affordable prenatal test for maternal and fetal health. Led by an experienced team, Ariosa is using its proprietary technology to perform a directed analysis of cell-free DNA in blood. The Harmony test equips pregnant women and their healthcare providers with reliable information to make decisions regarding their health, without creating unnecessary stress or anxiety.

The company was acquired by Roche in January 2015 with operations based in San Jose, Calif. For more information, visit www.ariosadx.com.


Management Team

John Stuelpnagel, DVM

John Stuelpnagel was Executive Chairman of Ariosa Diagnostics and now serves as a Special Advisor. Prior to Ariosa, John co-founded Illumina, Inc. and during his 12 years at Illumina, he served as the company's first CEO and most recently served as COO. Prior to Illumina, John was a venture capitalist at CW Group. John received his B.S. in Biochemistry and his Doctorate in Veterinary Medicine from the University of California, Davis and his M.B.A. from the University of California, Los Angeles.

Ken Song, MD
Chief Executive Officer

Ken Song brought together the initial team for Ariosa Diagnostics and has served as CEO since 2009. Prior to Ariosa, Ken was an investor at Venrock and led multiple investments in healthcare companies. Ken is a board certified physician, has extensive clinical and basic science research experience, and was previously a consultant at McKinsey & Company. Ken received his B.S. in Biology from the Massachusetts Institute of Technology and his M.D. from the University of California, San Francisco.

Dave Mullarkey
Chief Operating Officer

Dave Mullarkey oversees Ariosa's US and international commercial growth. He has over 25 years of healthcare experience. Prior to Ariosa, Dave led the growth of Valeant Pharmaceutical's dermatology business unit from $70 to $700M as Senior Vice President & General Manager. He started his career in sales with Eli Lilly and has managed businesses as well as led teams at companies such as Johnson & Johnson, Coopers & Lybrand Consulting, Dow Pharmaceutical Sciences and SCIREX (now Premier Research). Dave received his M.B.A. from the Kellogg School of Management at Northwestern University and B.S. from Cornell University.

Arnold Oliphant, PhD
Chief Scientific Officer

Arnold Oliphant has served as CSO of Ariosa Diagnostics since early 2010 and led development of the company's proprietary assay platform. Arnold has over 20 years of industry experience in developing and commercializing novel assays for research and clinical use. He has led multi-disciplinary research and development teams at Myriad Genetics, Illumina, and Complete Genomics. Arnold is an inventor on numerous patents and has co-authored several landmark papers in the field of human genetics. Arnold received his B.A. in Genetics from the University of Utah and his Ph.D. in Genetics from Harvard University.

Thomas Musci, MD
Chief Medical Officer

Thomas Musci oversees all efforts related to clinical trials and medical education for the Harmony test as well as other products in development. Recognized as a leader in clinical research on prenatal testing, Dr. Musci has served as chair of the Genetics Committee for the American Congress of Obstetricians and Gynecologists (ACOG), and he is currently a member of the Professional Practice Guidelines Committee for the American College of Medical Genetics (ACMG). He was co-founder of San Francisco Perinatal Associates, Inc., and retains an appointment as associate clinical professor with the Department of Obstetrics and Gynecology at University of California, San Francisco (UCSF).

Andrew Sparks, PhD
Senior Vice President, Development and Operations

Andrew Sparks joined Ariosa Diagnostics in 2010. Andrew is responsible for leading Ariosa's clinical lab operations, having successfully spearheaded development of Ariosa's assay platform. Andrew has over 15 years' experience developing and deploying large-scale genetic analysis technologies. Prior to joining Ariosa, Andrew led R&D and lab operation teams at Complete Genomics, Perlegen, and Affymetrix. Andrew has authored over 25 scientific publications, and is an inventor on over 15 patents. Andrew received his B.S. in Biology from the University of Texas, his Ph.D. in Genetics from the University of North Carolina, and was a postdoctoral fellow at Johns Hopkins University.

Margaret Theeuwes
Vice President, Marketing

Margaret Theeuwes is responsible for marketing in Ariosa. She has over 20 years of healthcare experience. Prior to Ariosa, Margaret held senior US and international marketing positions in pharmaceutical and consumer sectors of Johnson and Johnson including Janssen, Ortho Mc Neil and Neutrogena, in addition to her experience with In Home Care and healthcare pipeline consulting. Her areas of responsibility included development strategy, launch and marketing of pharmaceuticals in a variety of therapeutic areas including Dermatology, allergy, infectious disease and pain management. Margaret received her MD from the Catholic University of Leuven in Belgium, and BA in Biology from the University of California, at Santa Cruz.

Todd Rubano
Vice President, Informatics

Todd Rubano assumed responsibility in 2011 for automating the cutting-edge tests developed by the scientific team at Ariosa Diagnostics. Todd also leads teams in laboratory information systems, business applications and other information technology. Prior to joining Ariosa, Todd directed the Laboratory Automation & Systems Integration group at Illumina, Inc. He joined Illumina from Myriad Genetics where he led the engineering effort to automate the first commercially available DNA sequence-based test for breast cancer. Todd received his B.S. in Systems Engineering from University of Arizona and his M.E. in Engineering Systems from Colorado School of Mines.


Todd Whitson
Vice President, Sales and Commercial Operations

Todd Whitson joined Ariosa Diagnostics in 2011 as the first commercial hire of the organization. He is responsible for building the commercial team with an emphasis on sales and operations. Todd has held various sales leadership roles in healthcare over the last 10 years with increasing responsibility, most recently leading the integration of the combined oncology sales force for Genzyme Genetics and LabCorp. Prior to that, Todd led sales related activities at Genzyme Genetics for reproductive and oncology diagnostic products. Todd received his BA in Business/Economics and Psychology from Lafayette College and a Masters in Sports Administration from Richmond College.

Celeste McBride
Vice President, Operations

Celeste McBride joined Ariosa in 2010. She has 20 years of experience in the industry developing, managing and implementing large scale genotyping and sequencing operations. Celeste led successful process development teams and managed service laboratory operations at Myriad Genetics, Illlumina and Complete Genomics. She began her career in the Pathology department at Baylor College of Medicine and received her BS in Biology from University of Houston.

Sherwin Chen
Associate General Counsel

Sherwin Chen oversees all corporate, transactional, and compliance activities at Ariosa. Sherwin has 15 years of legal experience, with a focus on the life sciences industry. Prior to Ariosa, Sherwin practiced at the law firm of Cooley LLP in the Life Sciences group, providing counsel to private and public technology companies on corporate, M&A, and licensing and partnering matters. Sherwin was also Director and Corporate Counsel at FibroGen, Inc.  Sherwin  holds a B.S. in Biology from Stanford University, and received an M.S. from Rensselaer Polytechnic Institute, where he defended his thesis on prenatal diagnostic technologies. Sherwin received his J.D. from the UC Hastings College of the Law.

Natalie A. Cummins
VP, Market Access & Health Policy

Natalie Cummins oversees and executes all aspects of reimbursement including contracting and revenue cycle management. Natalie’s career focus has been on increasing market share and optimizing revenue through novel strategies and program development. Natalie has over 20 years of experience in strategic planning concentrated on health plan enrollment growth and launch of laboratory diagnostics. Prior to Ariosa, Natalie was an independent consultant providing reimbursement and contracting guidance to emerging genetic companies. Natalie’s’ experience also includes working for Quest Diagnostics with direct responsibility for health plan and payer marketing. In addition, Natalie has held leadership positions within health plans. Natalie received a Master’s Degree in Public Administration with a concentration in health policy from New York University and a Bachelors Degree in Health Administration from Ithaca College.